CrossAssetDataThe Company File
···
OFIX

Orthofix Medical Inc.

Orthofix Medical Inc. is classed by the SEC under Surgical & Medical Instruments & Apparatus (industry code 3841), based in Lewisville, TX. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $822 million and a loss of $92 million (its filed statements).

Product business Surgical & Medical Instruments & Apparatus Lewisville, TX filings since 1998 9 of 9 filed
Ask the desk about OFIX → Compare OFIX with TNDM → Price chart on TradingView ↗ Full EDGAR file ↗ Watch OFIX →

Sector peers: TNDMAORTGKOSNVCR

5.3/10headline grade
vs its business-model standard
5.2/10past 5.7/10present 4.9/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3841, Surgical & Medical Instruments & Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 5.3 out of ten, 9 of 9 metrics filed: past 5.2 out of ten, present 5.7 out of ten, future 4.9 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 8.3 out of ten. No warning events in its filings since 2017. 83rd percentile among 121 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 4.6 out of ten. +8% a year over 10 filed years; profitable in 4 of 10. 46th percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 2.0 out of ten. Share count grew 25.5% a year. 0% of cash flow returned. Insiders: 23 sales, 4 purchases. 20th percentile among 40 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 6.3 out of ten. ROE -20%: lost 20¢ per shareholder dollar. Leverage 47%: owes 47¢ per asset dollar. 63rd percentile among 120 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 6.7 out of ten. top 33% of 109 in its family; net margin -11.2%. 67th percentile among 109 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 3.2 out of ten. bottom 32% of 90 in its family for leadership; chief executive since 2024. 32nd percentile among 90 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 4.7 out of ten. bottom 47% of 104 in its family for room to expand. 47th percentile among 104 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 6.3 out of ten. top 37% of 105 in its family for growth drivers. 63rd percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 3.1 out of ten. bottom 31% of 88 in its family for expectations against reality. 31st percentile among 88 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-24 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-05 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-05 (on EDGAR). Newest filing: Form 4, 2026-10-05. Filings on record since 1998. Read from EDGAR 2026-10-12.

Where the revenue comes from

Lines of business in fiscal 2025: Global Spine 84%, Global Limb Reconstruction 16%. By geography: United States 83%, Other Countries 9%, Italy 3%, United Kingdom 2%, France 2%, Germany 1%. As tagged in its annual report (Form 10-K, filed 2026-02-24).

Who runs it

Calafiore, Massimo (President & CEO); Fisher, Patrick (President, Global Limb Recon); Reinhardt, Max (President, Global Spine); Andrews, Julie (CFO); Finegan, Michael (Chief Strategy Officer); Mcpherron, Aviva (Pres, Global Ops & Qual); Cedron, Jorge Andres (CLO); Vitale, Lucas (CP&BOO); Bazaar, Alan Lee (director); Burris, Wayne (director); and 6 more. 16 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-05.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.